Stada Arz buys UK OTC manufacturer

21 August 2013

German generic and branded drugmaker Stada Arzneimittel (SAZ: GR) signed and concluded a contract for the purchase of Thornton & Ross, a British OTC a UK manufacturer of over-the-counter (OTC) medicines located in Huddersfield, after STADA and the owners had already announced exclusive contract negotiations on this issue on August 6, 2013.

The purchase price amounts to £221,117,910 in cash. This corresponds to £193 million on a so-called cash and debt-free basis. Thornton & Ross has a number of well-known prescription-free (OTC) branded products for a wide variety of indications – among other things, cold, pain and dermatology.

Sales will presumably be consolidated in the Stada Group as of September 1, 2013. From that date, the transaction will also make a positive contribution to net income, the German company said.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK